齐拉西酮治疗精神分裂症疗效及不良反应的相关因素分析

doi:10.3969/j.issn.1006-7795.2016.02.011

首都医科大学学报 ›› 2016, Vol. 37 ›› Issue (2): 164-167.doi: 10.3969/j.issn.1006-7795.2016.02.011

齐拉西酮治疗精神分裂症疗效及不良反应的相关因素分析

朱虹¹, 贾竑晓¹, 阎爱国², 职利花¹

1. 首都医科大学附属北京安定医院中西医结合研究室北京重大脑疾病研究院精神分裂症研究所精神疾病诊断与治疗北京市重点实验室, 北京 100088;
2. 北京平谷区精神病医院4区, 北京 101201

收稿日期:2016-01-20 出版日期:2016-04-21 发布日期:2016-04-14
通讯作者: 贾竑晓 E-mail:jhxlj@vip.163.com
基金资助:
北京市自然科学基金(7152069),北京市科委首都临床特色应用研究专项(Z151100004015061)

Predictive factors for efficacy and adverse reactions of ziprasidone in schizophrenia patients

Zhu Hong¹, Jia Hongxiao¹, Yan Aiguo², Zhi Lihua¹

1. Research office of Integrated Traditional Chinese and Western Medicine, Beijing Anding Hospital, Capital Medical University, Center of Schizophrenia, Beijing Institute for Brain Disorders, Beijing Key Laboratory for Mental Disorders, Beijing 100088, China;
2. Ward No. 4 of Beijing Pinggu Psychiatric Hospital, Beijing 101201, China

Received:2016-01-20 Online:2016-04-21 Published:2016-04-14
Supported by:
This study was supported by Natural Science Foundation of Beijing (7152069), Clinical Characteristics Program of Beijing Municipal Science and Technology Commission (Z151100004015061).

摘要/Abstract

摘要： 目的分析70例经齐拉西酮治疗的精神分裂症患者疗效及锥体外系反应的相关因素。方法对70例经齐拉西酮治疗的精神分裂症患者的疗效及锥体外系反应的相关因素进行线性回归分析。结果疾病明显发作次数少是齐拉西酮疗效好的预测因素(β=-0.496, P=0.000);既往有无明显急性肌张力障碍和帕金森综合征、以阳性症状为主及疾病明显发作次数是有明显急性肌张力障碍和类帕金森综合征的预测因素(β分别为-0.634、0.332、-0.181,P分别为0.000、0.000、0.054);既往有明显静坐不能、疾病明显发作次数是明显静坐不能的预测因素(β分别为0.633、0.136, P分别为0.000、0.034)。阴性症状、病程长是齐拉西酮治疗有静坐不能的保护性因素(β分别为-0.310、-0.181,P分别为0.000、0.024)。结论疾病明显发作次数少的精神分裂症患者采用齐拉西酮治疗的疗效较好;既往有明显锥体外系反应史者、疾病明显发作次数少者应用齐拉西酮易发生明显锥体外系反应;以阴性症状为主、病程长的精神分裂症患者应用齐拉西酮不易发生静坐不能;以阳性症状为主者易发生急性肌张力障碍和类帕金森综合征。

关键词: 精神分裂症, 齐拉西酮, 疗效, 锥体外系反应, 预测因素

Abstract: Objective To analyze factors related to efficacy of ziprasidone and extrapyramidal symptom (EPS) in 70 schizophrenia patients treated with ziprasidone. Methods Multi linear Logistic regression was used to analyze factors related to efficacy of the treatment and extrapyramidal symptom in 70 schizophrenia patients treated with ziprasidone.Results Significant episodes of the disease were the predictor for the good effect of ziprasidone(β=-0.496, P=0.000). Previous history with acute dysmyotonia and Parkinson syndrome, prominent positive symptom, were the predictor for acute dysmyotonia and Parkinson syndrome(β=-0.634, 0.332 respectively, P=0.000 for both). Previous history of akathisia, prominent positive symptom, and relapse time of disease were the predictor for akathisia(β=0.633, 0.136 respectively, P=0.000, 0.034 respectively), prominent negative symptom and duration of disease were the protective factors for akathisia(β=-0.310, -0.181 respectively, P=0.000, 0.024 respectively).Conclusion Schizophrenia patients with few relapses of disease will demonstrate good therapeutic effect when treated with ziprasidone. Schizophrenia patients with previous history of extrapyramidal symptom, or with fewer relapses of disease may show higher occurrence of EPS; patients with prominent negative symptom, long duration of disease may predict lower occurrence of akathisia. Patients with prominent positive symptom may predict higher occurrence of acute dysmyotonia and Parkinson syndrome.

Key words: schizophrenia, ziprasidone, effect, extrapyramidal symptom, predictive factors

中图分类号:

R749.05

朱虹, 贾竑晓, 阎爱国, 职利花. 齐拉西酮治疗精神分裂症疗效及不良反应的相关因素分析[J]. 首都医科大学学报, 2016, 37(2): 164-167.

Zhu Hong, Jia Hongxiao, Yan Aiguo, Zhi Lihua. Predictive factors for efficacy and adverse reactions of ziprasidone in schizophrenia patients[J]. Journal of Capital Medical University, 2016, 37(2): 164-167.

参考文献

[1] American Psychiatric Association. Diagnostic and statistic manual of mental disorders[M].Washington D C:American Psychiatric Press, Inc., 2000.
[2] 易正辉,卢卫红,朱丽萍,等.第二代抗精神病药的进一步研究(三)利培酮早期反应预测后期疗效的研究[J].临床精神医学杂志,2004, 14(1):37-38.
[3] 卢晓星.影响精神分裂症患者抗精神病药物治疗效果的因素分析[J].重庆医学,2013,42(21):2473-2475.
[4] Lewis D A, Lieberman J A. Catching up on schizophrenia:natural history and neurobiology[J]. Neuron, 2000, 28(2):325-334.
[5] Keefe R S, McEvoy J P. Negative symptom and cognitive deficit treatment response in schizophrenia[M]. Washington DC:American Psychiatric Press, Inc., 2001, 163-175.
[6] Takeuchi H, Suzuki T, Bies R R,et al. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia:An analysis of the CATIE data[J]. Schizophr Res, 2013,150(2-3):373-379.
[7] Blaisdell G D. Akathisia:a comprehensive review and treatment summary[J]. Pharmacopsychiatry, 1994, 27(4):139-146.
[8] Lechin F, van der Dijs B.Noradrenergic hypothesis of schizophrenia[J]. Prog Neuro Psychopharmacol & Biological Psychiatry, 2005, 29(5):777-778.
[9] Stahl S M, Shayegan D K.The psychopharmacology of ziprasidone:receptor-binding properties and real-world psychiatric practice[J]. J Clin Psychiatry, 2003, 64 (Suppl 19):6-12.
[10] Comai S, Tau M, Pavlovic Z,et al. The psychopharmacology of aggressive behavior:a translational approach:part 2:clinical studies using atypical antipsychotics, anticonvulsants, and lithium[J]. J Clin Psychopharmacol, 2012,32(2):237-260.
[11] Olié J P, Spina E, Murray S,et al.Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia:results of a 12-week, double-blind study[J]. Int Clin Psychopharmacol, 2006, 21(3):143-151.
[12] Kuepper R, Skinbjerg M, Abi-Dargham A. The dopamine dysfunction in schizophrenia revisited:new insights into topography and course[J]. Handb Exp Pharmacol, 2012(212):1-26.

[1]	王庆莲, 滕颖, 乔文赢, 陈京龙, 丁晓燕. 比较不同方案治疗艾滋病相关伯基特淋巴瘤的疗效和安全性分析：一项单中心回顾性研究[J]. 首都医科大学学报, 2025, 46(3): 427-435.
[2]	闻竹, 张超, 张贤生. “五步法”经尿道钬激光前列腺剜除术对大体积前列腺增生患者术后尿控及性功能保护的影响[J]. 首都医科大学学报, 2025, 46(2): 263-268.
[3]	吴朝真, 郑华, 盛舒言, 张权, 张卉, 李杰, 吕嘉林, 钱哲, 王守正, 李曦, 胡瑛. 新辅助免疫联合化疗在非小细胞肺癌中的初步疗效观察[J]. 首都医科大学学报, 2024, 45(4): 642-648.
[4]	王居巳, 宋伟安, 狄守印, 刘军强, 范博士, 周少华, 岳彩迎, 赵嘉华, 陈思禹, 龚太乾. 新辅助化疗联合免疫抑制剂对Ⅲ期非小细胞肺癌治疗有效性分析[J]. 首都医科大学学报, 2024, 45(4): 660-665.
[5]	李冬月, 苏庆军, 张希诺, 陶鲁铭, 海涌. 单侧双通道与经皮椎间孔内镜下治疗腰椎间盘突出症的临床疗效比较[J]. 首都医科大学学报, 2024, 45(1): 149-155.
[6]	张颖, 王若梅, 李刚, 李璐莎. 综合心理干预对稳定期精神分裂症患者执行功能及社会功能的影响[J]. 首都医科大学学报, 2023, 44(5): 859-864.
[7]	郑思思, 宋明康, 宋楠, 朱虹, 贾竑晓. 度洛西汀治疗人格解体-现实解体障碍的探索性研究[J]. 首都医科大学学报, 2023, 44(4): 578-582.
[8]	仲捷, 朱虹, 郝军, 贾竑晓. 心理理论能力在稳定期精神分裂症精神症状与社会功能之间的中介作用[J]. 首都医科大学学报, 2023, 44(4): 590-595.
[9]	仲捷, 朱虹, 郑思思, 贾竑晓. 基于机器学习的急性期精神分裂症心理理论能力对社会功能的预测作用[J]. 首都医科大学学报, 2023, 44(4): 596-601.
[10]	罗炯, 孙丛丛, 潘伟刚, 王丹, 史晓宁, 王茜, 金文青, 梁立荣, 杨春林, 马辛, 任艳萍. 经颅交流电刺激联合抗抑郁药对抑郁发作的疗效及安全性[J]. 首都医科大学学报, 2022, 43(2): 244-248.
[11]	廉思源, 吴涵, 韩金祥, 肖存利, 任艳萍, 金文青, 王雯, 马辛. 影响精神分裂症自我报告康复效果的因素[J]. 首都医科大学学报, 2022, 43(2): 233-238.
[12]	任艳萍, 张俊岩, 吴涵, 罗炯, 杨春林, 马辛, 姜玮. 磁惊厥治疗与无抽搐电痉挛治疗抑郁发作的早期疗效及对认知功能的影响[J]. 首都医科大学学报, 2022, 43(2): 239-243.
[13]	李莉, 刘超猛, 任艳萍, 杨春林, 马辛. 改良电休克治疗首发精神分裂症的研究进展[J]. 首都医科大学学报, 2022, 43(2): 249-253.
[14]	郭城伟, 周娇娇, 冯媛, 杨蕴萍. 精神分裂症患者与正常人自尊水平的对照研究[J]. 首都医科大学学报, 2022, 43(2): 294-298.
[15]	朱平, 禹环, 符丽梅, 廖欣, 熊暮珺, 雷阿明, 祝平安, 梁欣荃. 脐血移植治疗难治复发急性白血病的临床分析[J]. 首都医科大学学报, 2021, 42(6): 1041-1045.

齐拉西酮治疗精神分裂症疗效及不良反应的相关因素分析

Predictive factors for efficacy and adverse reactions of ziprasidone in schizophrenia patients

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价